Compare iShares MSCI Singapore ETF (EWS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Singapore ETF trades at $31.22 (market cap $1.23B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 4.1× iShares MSCI Singapore ETF's market cap, and Travere Therapeutics Inc. Common Stock is more actively traded (2,060,842 versus 1,492,494). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 47 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWS | TVTX | |
|---|---|---|
Market Cap | $1.23B | $5.02B |
Volume | 1,492,494 | 2,060,842 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $67.52 |
52-Week Low | $26.71 | $26.79 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $31.54, down slightly by 0.03% on the day. Technical indicators are mixed, with moving averages signaling a bearish trend while oscillators suggest potential oversold conditions. The ETF recently hit a 52-week high, driven by Singapore's strong economic growth and AI momentum. Institutional interest is positive, with Amundi increasing its stake by 4.8% as of its latest 13F filing.
The outlook for EWS is cautiously optimistic, supported by Singapore's resilient economy and institutional inflows. Key risks include stretched valuations after the multi-year rally and sensitivity to regional economic shifts. Investors should weigh the strong momentum against potential pullbacks in a high-valuation environment.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
